1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Venous Diseases Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Porter’s Five Force Analysis
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Technological Advancements
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. Reimbursement Scenario by Region/globally
6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Surgeries
6.3.1.1. Angioplasty or Stenting
6.3.1.2. Vein Ligation and Stripping
6.3.1.3. Vena Cava Filter
6.3.1.4. Ambulatory Phlebectomy
6.3.1.5. Others
6.3.2. Therapies
6.3.2.1. Sclerotherapy
6.3.2.2. Radiofrequency Ablation Therapy
6.3.2.3. Laser Treatment
6.4. Market Attractiveness Analysis, by Treatment
7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017–2031
7.3.1. Deep-vein Thrombophlebitis
7.3.2. Varicose Veins
7.3.3. Superficial Thrombophlebitis
7.3.4. Chronic Venous Insufficiency
7.3.5. Venous Ulcers
7.3.6. Others
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Product Type, 2017–2031
8.3.1. Ablation Devices
8.3.2. Venous Stents
8.3.3. Venous Closure Treatments
8.3.4. Sclerotherapy Injection
8.3.5. Others
8.4. Market Attractiveness Analysis, by Product Type
9. Global Venous Diseases Treatment Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Ambulatory centers
9.4. Market Attractiveness Analysis, by End-user
10. Global Venous Diseases Treatment Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Venous Diseases Treatment Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Surgeries
11.2.1.1. Angioplasty or Stenting
11.2.1.2. Vein Ligation and Stripping
11.2.1.3. Vena Cava Filter
11.2.1.4. Ambulatory Phlebectomy
11.2.1.5. Others
11.2.2. Therapies
11.2.2.1. Sclerotherapy
11.2.2.2. Radiofrequency Ablation Therapy
11.2.2.3. Laser Treatment
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Deep-vein Thrombophlebitis
11.3.2. Varicose Veins
11.3.3. Superficial Thrombophlebitis
11.3.4. Chronic Venous Insufficiency
11.3.5. Venous Ulcers
11.3.6. Others
11.4. Market Value Forecast, by Product Type, 2017–2031
11.4.1. Ablation Devices
11.4.2. Venous Stents
11.4.3. Venous Closure Treatments
11.4.4. Sclerotherapy Injection
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Ambulatory centers
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Disease Type
11.7.3. By Product Type
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Venous Diseases Treatment Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Surgeries
12.2.1.1. Angioplasty or Stenting
12.2.1.2. Vein Ligation and Stripping
12.2.1.3. VeEnd Use Cava Filter
12.2.1.4. Ambulatory Phlebectomy
12.2.1.5. Others
12.2.2. Therapies
12.2.2.1. Sclerotherapy
12.2.2.2. Radiofrequency Ablation Therapy
12.2.2.3. Laser Treatment
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Deep-vein Thrombophlebitis
12.3.2. Varicose Veins
12.3.3. Superficial Thrombophlebitis
12.3.4. Chronic Venous Insufficiency
12.3.5. Venous Ulcers
12.3.6. Others
12.4. Market Value Forecast, by Product Type, 2017–2031
12.4.1. Ablation Devices
12.4.2. Venous Stents
12.4.3. Venous Closure Treatments
12.4.4. Sclerotherapy Injection
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Ambulatory centers
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.7. Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Disease Type
12.7.3. By Product Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Venous Diseases Treatment Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Surgeries
13.2.1.1. Angioplasty or Stenting
13.2.1.2. Vein Ligation and Stripping
13.2.1.3. VeEnd Use Cava Filter
13.2.1.4. Ambulatory Phlebectomy
13.2.1.5. Others
13.2.2. Therapies
13.2.2.1. Sclerotherapy
13.2.2.2. Radiofrequency Ablation Therapy
13.2.2.3. Laser Treatment
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Deep-vein Thrombophlebitis
13.3.2. Varicose Veins
13.3.3. Superficial Thrombophlebitis
13.3.4. Chronic Venous Insufficiency
13.3.5. Venous Ulcers
13.3.6. Others
13.4. Market Value Forecast, by Product Type, 2017–2031
13.4.1. Ablation Devices
13.4.2. Venous Stents
13.4.3. Venous Closure Treatments
13.4.4. Sclerotherapy Injection
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Ambulatory centers
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Treatment
13.7.2. By Disease Type
13.7.3. By Product Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Venous Diseases Treatment Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Surgeries
14.2.1.1. Angioplasty or Stenting
14.2.1.2. Vein Ligation and Stripping
14.2.1.3. VeEnd Use Cava Filter
14.2.1.4. Ambulatory Phlebectomy
14.2.1.5. Others
14.2.2. Therapies
14.2.2.1. Sclerotherapy
14.2.2.2. Radiofrequency Ablation Therapy
14.2.2.3. Laser Treatment
14.3. Market Value Forecast, by Disease Type, 2017–2031
14.3.1. Deep-vein Thrombophlebitis
14.3.2. Varicose Veins
14.3.3. Superficial Thrombophlebitis
14.3.4. Chronic Venous Insufficiency
14.3.5. Venous Ulcers
14.3.6. Others
14.4. Market Value Forecast, by Product Type, 2017–2031
14.4.1. Ablation Devices
14.4.2. Venous Stents
14.4.3. Venous Closure Treatments
14.4.4. Sclerotherapy Injection
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Ambulatory centers
14.6. Market Value Forecast, by Country/Sub-region, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Disease Type
14.7.3. By Product Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017–2031
15.2.1. Surgeries
15.2.1.1. Angioplasty or Stenting
15.2.1.2. Vein Ligation and Stripping
15.2.1.3. VeEnd Use Cava Filter
15.2.1.4. Ambulatory Phlebectomy
15.2.1.5. Others
15.2.2. Therapies
15.2.2.1. Sclerotherapy
15.2.2.2. Radiofrequency Ablation Therapy
15.2.2.3. Laser Treatment
15.3. Market Value Forecast, by Disease Type, 2017–2031
15.3.1. Deep-vein Thrombophlebitis
15.3.2. Varicose Veins
15.3.3. Superficial Thrombophlebitis
15.3.4. Chronic Venous Insufficiency
15.3.5. Venous Ulcers
15.3.6. Others
15.4. Market Value Forecast, by Product Type, 2017–2031
15.4.1. Ablation Devices
15.4.2. Venous Stents
15.4.3. Venous Closure Treatments
15.4.4. Sclerotherapy Injection
15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Ambulatory centers
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
16. Competitive Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Zimmer Biomet Holdings, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Medtronic
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. AngioDynamics
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Alma Lasers
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Biolitec AG Untere Viaduktgasse
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Becton, Dickinson and Company
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Boston Scientific Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Abbott Laboratories
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. B. Braun Melsungen AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Teleflex Incorporated
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Lumenis
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. Philips
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Company Financials
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer